探讨保妇康栓联合加味四妙汤，治疗真菌性阴道炎和人乳头瘤病毒(HPV)感染的临床疗效。

选择2017年3月至2018年3月，于承德市中心医院进行治疗的120例真菌性阴道炎患者和120例HPV感染患者为研究对象。采用随机数字表法，将120例真菌性阴道炎患者，分别纳入观察组-1(n＝60)、对照组-1(n＝60)；而将120例HPV感染患者，则分别纳入观察组-2(n＝60)、对照组-2(n＝60)。对观察组-1和观察组-2患者，均采取保妇康栓＋加味四妙汤治疗；而对于对照组-1和对照组-2患者，则均单纯采取保妇康栓进行治疗。采用成组t检验及χ²检验，分别对观察组-1与对照组-1，以及观察组-2与对照组-2的患者年龄、病程，以及治疗总有效率、不良反应发生率等疗效评价指标，进行统计学比较。本研究遵循的程序符合2013年修订的《世界医学协会赫尔辛基宣言》。所有患者及其家属对所采用的治疗方案等，均知情同意，并签署临床研究知情同意书。

①观察组-1与对照组-1患者年龄、病程、外阴不适发生率及性交痛发生率比较，差异均无统计学意义(P>0.05)。观察组-1患者的治疗总有效率为93.3%，显著高于对照组-1患者的75.0%；观察组-1患者真菌性阴道炎复发率为5.0%，显著低于对照组-1患者的23.3%，并且差异均有统计学意义(χ²＝6.968、P＝0.012，χ²＝6.511、P＝0.016)。②观察组-2与对照组-2患者年龄，病程，治疗前血清肿瘤坏死因子(TNF)-α及α-干扰素水平，以及外阴不适、小腹疼痛、白带异常及接触性出血发生率比较，差异均无统计学意义(P>0.05)。观察组-2患者的治疗总有效率，HPV转阴率，治疗后TNF-α及α-干扰素水平分别为88.3%、83.3%、(8.78±0.12) ng/L及(7.69±0.45) ng/L，均显著高于对照组-2患者的71.7%、63.3%、(6.97±0.17) ng/L及(6.45±0.34) ng/L，并且差异均有统计学意义(χ²＝6.097、P＝0.041，χ²＝7.156、P＝0.012，t＝6.214、P＝0.026，t＝5.861、P＝0.048)。

保妇康栓联合加味四妙汤治疗真菌性阴道炎和HPV感染，较单纯保妇康栓治疗的临床治疗效果更好。

To evaluate the clinical curative effect of baofukang suppository combined with modified simiao decoction on treatment of colpitis mycotica and human papilloma virus (HPV) infection.

A total of 120 cases of colpitis mycotica and 120 cases of HPV infection patients who were admitted in Chengde Central Hospital from March 2017 to March 2018 were chosen as research objects. With the random number table method, 120 colpitis mycotica patients were divided into observation group-1 (n=60) and control group-1 (n=60), respectively; while other 120 HPV infection patients were divided into observation group-2 (n=60) and control group-2 (n=60), respectively. The observation group-1 and observation group-2 were both treated with baofukang suppository combined with modified simiao decoction; while control group-1 and control group-2 were both only treated with baofukang suppository. The patients′ age, course of disease, and curative effect evaluation indexes including total effective rate and adverse reaction rates etc., were compared between observation group-1 and control group-1, also between observation group-2 and control group-2 by independent-samples t test and chi-square test. This study was consistent with World Medical Association Declaration of Helsinki revised in 2013. All patients and their family members were informed and signed the informed contents.

①There were no significant differences between observation group-1 and control group-1 in patients′ age, course of disease, incidence rates of vulvar discomfort and algopareunia (P>0.05). The total effective rate of observation group-1 was 93.3%, which was significantly higher than that of 75.0% in control group-1; while the colpitis mycotica recurrence rate of observation group-1 was 5.0%, which was significantly lower than that of 23.3% in control group-1, and the differences were statistically significant (χ²=6.968, P=0.012; χ²=6.511, P=0.016). ② There were no significant differences between observation group-2 and control group-2 in patients′ age, course of disease, levels of serum tumor necrosis factor (TNF)-α and interferon-α before treatment, as well as the incidence rates of vulvar discomfort, lower abdominal pain, leucorrhea abnormality and contact bleeding (P>0.05). The total effective rate, HPV negative conversion rate, and levels of TNF-α and interferon-α after treatment in observation group-2 were 88.3%, 83.3%, (8.78±0.12) ng/L and (7.69±0.45) ng/L, which were significantly higher than those of 71.7%, 63.3%, (6.97±0.17) ng/L and (6.45±0.34) ng/L in control group-2, and the differences were statistically significant (χ²=6.097, P=0.041; χ²=7.156, P=0.012; t=6.214, P=0.026; t=5.861, P=0.048).

Baofukang suppository combined with modified simiao decoction would have better therapeutic effect than use baofukang suppository only in treatment of colpitis mycotica and HPV infection.